PLAUR and sarcoma: Although the differential sensitivity of cell lines to the toxin may play a role, the increased potency may likely result from the BLTs’ superior binding affinity (due to avidity effects) to dual-receptor expressing cells, EGFR- and uPAR-expressing cells in the case of eBAT, as confirmed by flow-cytometry analysis in GBM cells and, recently, in other sarcoma and ovarian cancer cell lines.